Background: Osteoporosis is a silent skeletal disorder characterized by reduced bone strength, increasing the risk of fractures. It significantly impacts the health-related quality of life (HRQoL) of postmenopausal women. Teriparatide, a recombinant parathyroid hormone analog, is approved for the treatment of postmenopausal osteoporosis. However, the long-term effects on HRQoL after discontinuation of teriparatide remain underexplored. Methods: This study was conducted at the Physical Medicine and Rehabilitation Department, SMS Medical College, Jaipur. A cohort of 35 postmenopausal women (>45 years) with osteoporosis who had undergone 24 months of teriparatide treatment were recruited. Exclusion criteria included the use of other anti-resorptive therapies post-teriparatide. HRQoL was assessed using the Short Form-36 (SF-36) questionnaire and pain was measured using the Visual Analogue Scale (VAS) for back pain at baseline (immediately after discontinuing teriparatide) and after one year. Demographic data and bone mineral density (BMD) were also collected. Results: The mean age of participants was 62.43 ± 9.26 years, with a mean BMI of 24.78 ± 4.94 kg/m². After one year of discontinuation, the VAS pain score showed a non-significant increase from 2.86 ± 0.73 to 2.96 ± 0.69 (p > 0.05). Among the SF-36 domains, all showed no significant change except for social functioning, which significantly decreased (p < 0.05). Tables and figures illustrating demographic characteristics, VAS score changes, and SF-36 domain alterations are presented. Conclusion: Discontinuation of teriparatide treatment in postmenopausal osteoporotic women is associated with a slight, non-significant increase in back pain and a significant decline in social functioning aspects of HRQoL. Sequential anti-resorptive therapy post-teriparatide may be beneficial to sustain quality of life improvements.